Cargando…

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model

Detalles Bibliográficos
Autores principales:	Despiegel, Nicolas, Kuehne, Felicitas, Martin, Monique, Shelbaya, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360387/ http://dx.doi.org/10.1186/1742-4690-9-S1-P60

Ejemplares similares

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
por: Bregigeon, Sylvie, et al.
Publicado: (2010)

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
por: Furtado, JJD, et al.
Publicado: (2010)

Magnetic assessment and modelling of the Aramis undulator beamline
por: Calvi, M., et al.
Publicado: (2018)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
por: Poveda, Eva, et al.
Publicado: (2010)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

HIV entry blocked by maraviroc can cause an overestimation of viral load
por: Sloan, RD, et al.
Publicado: (2010)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

SwissFEL Aramis beamline photon diagnostics
por: Juranic, Pavle, et al.
Publicado: (2018)

SwissFEL Aramis beamline photon diagnostics
por: Juranić, Pavle, et al.
Publicado: (2018)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman
por: Feiterna-Sperling, Cornelia, et al.
Publicado: (2019)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

ARAMyS – Alignment Reconstruction Software for the ATLAS Muon Spectrometer
por: Amelung, C
Publicado: (2007)

SwissFEL Aramis beamline photon diagnostics. Erratum
por: Juranić, Pavle, et al.
Publicado: (2019)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

P09-03 Costing the economic burden of sedentary behaviors in France
por: Racine, Antoine Noël, et al.
Publicado: (2022)

Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Difficulties in controlling HIV and TB infections in multi-experienced patients
por: Benea, Șerban, et al.
Publicado: (2014)

Estimation of HIV incidence in Brazil, 2005-2011
por: Szwarcwald, Celia Landmann, et al.
Publicado: (2014)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

Transmission measurement at the Bernina branch of the Aramis Beamline of SwissFEL
por: Juranic, Pavle, et al.
Publicado: (2019)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy
por: Gaytán-Martínez, JE, et al.
Publicado: (2010)

The cases with opportunistic infections among HIV patients in Indonesia 2011
por: Rusli, Roselinda, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

P01-11 Economic impact of health-enhancing-physical activity from different settings in France
por: Racine, Antoine Noël, et al.
Publicado: (2022)

Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)
por: Pérez, L, et al.
Publicado: (2010)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

ARAMIS: From systematic errors of NGS long reads to accurate assemblies
por: Sacristán-Horcajada, E, et al.
Publicado: (2021)

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
por: Jacqmin, P, et al.
Publicado: (2013)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
por: Doroana, M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7kc2mpv5rhg7ne67anbnglrtvu